Drug intelligence / Profile preview

GSK1247303

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules

Overview

GSK1247303 is an investigational small molecule drug developed by GlaxoSmithKline as an integrase inhibitor. Its primary mechanism of action is the inhibition of the HIV integrase enzyme, which is essential for the integration of viral DNA into the host genome—a critical step in HIV replication. The compound was evaluated in a first-in-human Phase 1 clinical trial involving healthy volunteers but development was terminated at this early stage. There are no approved indications or known adverse events reported for this agent[2][3].

Targets

Integrase allosteric pocket (HIV)

Beyond the preview

Go deeper on GSK1247303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK1247303.

Explore the full profile